Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts... Show more
Boston Scientific has spent recent years delivering outsized growth, driven by strong performance in its electrophysiology (EP, or heart-rhythm) and WATCHMAN franchises. This quarter marks a turning point, as both businesses began to weigh on overall results amid rising competition and evolving clinical evidence. The August cybersecurity incident compounded the challenge, disrupting global operations for roughly eight days and pressuring sales and margins. For investors, the report matters because it tests whether the company's diversification can offset slowing momentum in two historically high-growth areas. The sharp downward revision to guidance also signals that management expects the pressure to persist into 2027, making this an important checkpoint for the company's longer-term growth thesis.
Boston Scientific posted net sales of $5.138 billion for the third quarter ended September 30, 2026, a 1.5% increase from $5.065 billion in the prior-year period. The result narrowly exceeded the consensus estimate of about $5.12 billion. Adjusted EPS of $0.73 declined 3% year over year and landed slightly below the approximately $0.75 analyst consensus, while GAAP net income attributable to common stockholders fell to $582 million, or $0.40 per diluted share.
By segment, Cardiovascular revenue rose 1.9% to $3.41 billion, while MedSurg revenue increased 0.6% to $1.73 billion. Within the portfolio, WATCHMAN sales declined 6% and electrophysiology sales fell 5%, reflecting softer left atrial appendage closure (LAAC, a procedure to reduce stroke risk) trends and pulsed field ablation (PFA, a catheter-based heart treatment) share erosion. Management estimated the cybersecurity incident reduced organic revenue growth by roughly 300 bps and adjusted EPS by about $0.07.
Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, giving investors a structured way to surface ideas aligned with their own criteria.
Shares of Boston Scientific fell sharply following the report, with the stock dropping as much as 8% in early trading before paring losses. The decline reflected investor disappointment over the earnings miss, the steep reduction in fourth-quarter and full-year guidance, and the acknowledgment that competition in EP and WATCHMAN has intensified. The market's reaction underscored that the headline revenue beat was outweighed by weaker profitability, margin contraction, and a cautious outlook. Sentiment heading into the print had already been cautious, and the combination of cyber-related disruption and lower forward expectations reinforced concerns that the company's rapid growth phase has cooled.
Boston Scientific guided fourth-quarter 2026 organic revenue to decline 1% to 3%, with adjusted EPS of $0.77 to $0.79, both below consensus. For the full year, the company now expects reported sales growth of about 4.25% and adjusted EPS of $3.16 to $3.18, down from its prior range of $3.28 to $3.32.
Looking ahead, management described 2027 as the trough of the current cycle and cautioned that revenue and adjusted EPS will be challenged to grow, excluding the pending Penumbra acquisition. Investors should monitor several catalysts: the timing of the FARAWAVE Ultra launch, now expected in early 2028; the ramp of the SEISMIQ intravascular lithotripsy platform; and the eventual close of the Penumbra deal, anticipated in early 2027.
Margin recovery will also be a key watch item as the company works through post-cyber manufacturing absorption issues and a restructuring program expected to generate more than $500 million in savings over three years. Pricing pressure in China adds another layer of uncertainty, but management expects these actions to support a return to stronger performance in 2028.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a maker of medical devices
Industry MedicalNursingServices